Applicability of Routine Targeted Next-generation Sequencing to Estimate Tumor Mutational Burden (TMB) in Patients Treated With Immune Checkpoint Inhibitor Therapy

被引：2

作者：

Pinato, David J. ^{[1
,2
]}

Urus, Heather ^{[1
,2
]}

Newsom-Davis, Thomas ^{[3
]}

Du Parcq, Persephone ^{[4
]}

Belessiotis, Katherine ^{[2
]}

Mapara, Leah ^{[2
]}

Gupta, Nandita ^{[5
]}

Power, Danielle ^{[2
]}

Weir, Justin ^{[5
]}

Wong, Ching Ngar ^{[1
]}

Ratnakumaran, Ragu P. ^{[2
]}

Dominy, Kathy ^{[4
]}

Khorashad, Jamshid ^{[4
]}

Bower, Mark ^{[3
]}

机构：

[1] Imperial Coll London, Dept Surg & Canc, London, England

[2] Imperial Coll NHS Trust, Charing Cross Hosp, Dept Oncol, London, England

[3] Chelsea & Westminster Hosp, Dept Oncol, London, England

[4] Hammersmith Hosp, Mol Pathol Lab, London, England

[5] Imperial Coll NHS Trust, Hammersmith Hosp, Dept Histopathol, London, England

来源：

JOURNAL OF IMMUNOTHERAPY | 2020年 / 43卷 / 02期

基金：

英国惠康基金;

关键词：

TMB; immunotherapy; targeted; NGS; panel;

D O I：

10.1097/CJI.0000000000000295

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

It remains unclear whether targeted next-generation sequencing (tNGS) conveys a reliable estimate of tumor mutational burden (TMB). We sequenced 79 archival samples of immune checkpoint inhibitors (ICPIs) recipients (57% lung cancer, 43% melanoma) using Ion Ampliseq Cancer Hotspot Panel. Employing multiple cutoff values, we verified that TMB by tNGS did not correlate with response or survival following ICPI. We found enrichment of ATM mutations in ICPI-refractory tumors (P=0.01) to correlate with worse survival (4.2 vs. 10 mo, P=0.03). Limited-coverage tNGS delivers an imprecise estimate of patients' TMB but may aid identification of candidate somatic variants of predictive/prognostic significance.

引用

页码：53 / 56

页数：4

共 50 条

[1] Next-generation sequencing of circulating tumor DNA in advanced lung cancer patients treated with the immune checkpoint inhibitor.
Cho, William C.
Hsiao, Wen
Tan, Kien Thiam
Li, Jacky Y.
Chen, Shu-Jen
CANCER RESEARCH, 2021, 81 (13)
[2] Calculation of Tumor Mutational Burden (TMB) Using a Small, Targeted Next-Generation Sequencing (NGS) Panel for Solid Tumor Samples Absent Matched Normal Samples
Velu, P. D.
Oldridge, D. A.
Bidgeli, A.
Sussman, R.
Rosenbaum, J. N.
Faryabi, R. B.
JOURNAL OF MOLECULAR DIAGNOSTICS, 2019, 21 (06): : 1178 - 1178
[3] Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer
Ricciuti, Biagio
Kravets, Sasha
Dahlberg, Suzanne E.
Umeton, Renato
Albayrak, Adem
Subegdjo, Safiya J.
Johnson, Bruce E.
Nishino, Mizuki
Sholl, Lynette M.
Awad, Mark M.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[4] Development and analytical validation of a plasma-based tumor mutational burden (TMB) score from next-generation sequencing panels
Quinn, K.
Helman, E.
Nance, T.
Artieri, C.
Yen, J.
Zhao, J.
Fairclough, S.
Sikora, M.
Chudova, D.
Lanman, R. B.
Talasaz, A.
ANNALS OF ONCOLOGY, 2018, 29
[5] Tumor mutational burden (TMB) in immune checkpoint inhibitor (ICI)-naive and -experienced patients with metastatic melanoma treated with lifileucel, a tumorinfiltrating lymphocyte (TIL) cell therapy.
Kluger, Harriet M.
Sarnaik, Amod
Chesney, Jason Alan
Lewis, Karl D.
Weber, Jeffrey S.
Gogas, Helen
In, Gino Kim
Terheyden, Patrick Andres Maximilian
Lee, Sylvia
Jagasia, Madan H.
Masteller, Emma
Qi, Rongsu
Gontcharova, Viktoria
Shi, Wen
Fiaz, Rana
Sulur, Giri
Wu, Renee Xiao
Chen, Guang
Thomas, Sajeve Samuel
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[6] Optimisation and qualification of tumour mutational burden (TMB) by targeted next-generation sequencing (TNGS) as a clinically applicable biomarker in hepatocellular carcinoma (HCC)
Wong, Ching Ngar
Dominy, Kathy
Mauri, Francesco
Kaneko, Takahiro
Du Parcq, Persephone
Khorasad, Jamshid
Toniutto, Pierluigi
Goldin, Robert D.
Avellini, Claudio
Pinato, David J.
JOURNAL OF HEPATOLOGY, 2020, 73 : S374 - S375
[7] Mutational spectrum of Chinese LGMD patients by targeted next-generation sequencing
Yu, Meng
Zheng, Yiming
Jin, Suqin
Gang, Qiang
Wang, Qingqing
Yu, Peng
Lv, He
Zhang, Wei
Yuan, Yun
Wang, Zhaoxia
PLOS ONE, 2017, 12 (04):
[8] Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma
Wong, Ching Ngar
Fessas, Petros
Dominy, Kathy
Mauri, Francesco A.
Kaneko, Takahiro
Parcq, Persephone Du
Khorashad, Jamshid
Toniutto, Pierluigi
Goldin, Robert D.
Avellini, Claudio
Pinato, David J.
LIVER INTERNATIONAL, 2021, 41 (01) : 192 - 203
[9] Targeted Next-Generation Sequencing Reveals High Mutational Burden in Aggressive Thyroid Cancers
Kleinlein, Irene
Pfarr, Nicole
Haller, Bernhard
Keller, Gisela
Fuerst, Heinrich
Weichert, Wilko
Kremer, Marcus
MODERN PATHOLOGY, 2018, 31 : 232 - 233
[10] Targeted Next-Generation Sequencing Reveals High Mutational Burden in Aggressive Thyroid Cancers
Kleinlein, Irene
Pfarr, Nicole
Haller, Bernhard
Keller, Gisela
Fuerst, Heinrich
Weichert, Wilko
Kremer, Marcus
LABORATORY INVESTIGATION, 2018, 98 : 232 - 233

← 1 2 3 4 5 →